Surgalign announces commercial launch of ViBone Moldable » 09:1901/1201/12/21
Surgalign Holdings announced the commercial launch and the completion of the first surgery of ViBone Moldable in the US. The first implantation was completed by Dr. Adam Crowl, at OrthoVirgina in Midlothian, VA. ViBone Moldable is the newest orthobiologics solution of Surgalign's bone graft portfolio to support spinal fusion, which currently include ViBone and other advanced bone graft solutions.
|Over a week ago|
Surgalign files to sell $86.25M of common stock 17:1112/3012/30/20
|Over a month ago|
Fly Intel: Top five analyst initiations » 09:5311/3011/30/20
PI, LLNW, SPGI, QS, SRGA
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Impinj (PI) initiated with a Buy at Goldman Sachs. 2. Limelight Networks (LLNW) initiated with a Neutral at Goldman Sachs. 3. S&P Global (SPGI) initiated with a Buy at Deutsche Bank. 4. QuantumScape (QS) initiated with an Underperform at Bernstein. 5. Surgalign (SRGA) initiated with a Buy at Lake Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Surgalign initiated with a Buy at Lake Street » 09:0811/3011/30/20
Lake Street analyst…
Lake Street analyst Brooks O'Neil initiated coverage of Surgalign with a Buy rating and $8 price target. The company is now a pure-play spine company after the former RTI Holdings sold its OEM business and acquired surgical technology maker Holo Surgical, noted O'Neil, who expects Surgalign to "continue to move decisively" to take share in the spine market.
Surgalign appoints Paul Lewicki to board of directors » 09:0611/2311/23/20
Surgalign Holdings announced the appointment of Paul Lewicki, PhD as a member of its board of directors. With Dr. Lewicki's appointment the Surgalign Board now consists of nine directors. Prior to its acquisition by Surgalign, Dr. Lewicki served as President of Holo Surgical.
Surgalign, Aziyo Biologics update distribution pact » 16:2511/1611/16/20
Surgalign Holdings (SRGA)…
Surgalign Holdings (SRGA) and Aziyo Biologics (AZYO), a commercial-stage regenerative medicine company, announced an updated distribution agreement and expanded product offering whereby Aziyo will provide ViBone(R) Moldable to Surgalign for distribution in the U.S. ViBone Moldable joins Surgalign's orthobiologic solutions to support spinal fusion, which currently include ViBone and other advanced bone graft solutions.
Omega takes Alphabet Class A stake, exits position in JPMorgan » 12:1111/1611/16/20
GOOGL, ATH, VRT, MSI, JPM, CNC, GTN, VICI, DEN, COOP, OCN, ASPU, FCRD, NAVI, CI, PE, SRGA, GCI, NBR, FISV, TRN
Leon Cooperman's Omega Advisors disclosed in an SEC filing its holdings as of September 30, 2020. Omega's seven new buys during the third quarter included, by size of position, Alphabet (GOOGL), Athene Holding (ATH), Vertiv Holdings (VRT), and Motorola Solutions (MSI). Omega exited six positions during the quarter, including by size of previous position, JPMorgan (JPM). Centene (CNC), Gray Television (GTN), Vici Properties (VICI), and Denbury (DEN). Omega increased its stake in 14 holdings, including by size of previous position, Mr. Cooper (COOP), Ocwen Financial (OCN), Aspen Group (ASPU), First Eagle Alternative Capital (FCRD), and Navient (NAVI). Omega reduced its stake in seven holdings, including by size of previous position, Cigna (CI), Parsley Energy (PE), Surgalign Holdings (SRGA), Gannett (GCI), and Nabors (NBR). Omega's top holdings as of September 30, in order of size, were Fiserv (FISV), Mr. Cooper, Alphabet, Cigna, and Trinity Industries (TRN).
|Over a quarter ago|
Surgalign to acquire Holo Surgical for up to $125M » 19:0509/2909/29/20
Surgalign Holdings announces that it has entered into a definitive agreement to acquire Holo Surgical Inc., a Chicago-based private technology company developing Augmented Reality and Artificial Intelligence platform, to enable digital spine surgery. Total consideration for the transaction is valued at up to $125M, consisting of consideration valued at $42M payable at closing in cash and shares plus potential future milestone payments. The transaction is expected to close during the fourth quarter of 2020, subject to customary closing conditions.
Surgalign not providing FY20 financial guidance » 07:2708/0708/07/20
The company said,…
The company said, "Due to the inability to estimate the size and impact of the COVID - 19 pandemic on the Company's operations and financial results, Surgalign Holdings, Inc. is not providing guidance for fiscal 2020. We will continue to evaluate the impact of the COVID - 19 pandemic on our operations and financial results and will provide additional information when we are more certain."
Surgalign reports Q2 EPS (51c) vs. 0c last year » 07:2608/0708/07/20
ReportsQ2 revenue $54.23M…
ReportsQ2 revenue $54.23M vs. $81.56M last year. "These are very exciting times as we have officially launched Surgalign as a global pure-play spine company," said Terry Rich, President and Chief Executive Officer of Surgalign Holdings. "We are in a tremendous position to capitalize on the opportunity that lies ahead. Supported by a strong balance sheet and a best-in-class team, we look to build on the foundation of the RTI Surgical spine business to advance care and improve patient outcomes. During the second quarter, we saw a solid return of demand in June, which continued in July as COVID began to experience a resurgence in some major markets in the U.S. We remain cautiously optimistic about the recovery of the procedure volumes during the balance of the year. Regardless of the near-term uncertainty, we continue to progress with our investments to build, innovate, and acquire, furthering our confidence to drive profitable double-digit topline growth over the long term."